Nelly Ahouansou1, Marjolaine Georges2, Guillaume Beltramo3, Nicolas Aswad1, Yasmina Hassani1, Philippe Bonniaud3. 1. Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence Constitutif des maladies Pulmonaires rares de l'Adultes de Dijon, réseau OrphaLung, Filère RespiFil, Centre Hospitalier Universitaire de Bourgogne, 14, rue Paul-Gaffarel, 21000 Dijon, France. 2. Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence Constitutif des maladies Pulmonaires rares de l'Adultes de Dijon, réseau OrphaLung, Filère RespiFil, Centre Hospitalier Universitaire de Bourgogne, 14, rue Paul-Gaffarel, 21000 Dijon, France; Université de Bourgogne Franche-Comté, Faculté de médecine, Dijon, France; NSERM U123-1, Dijon, France. Electronic address: marjolaine.georges@chu-dijon.fr. 3. Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence Constitutif des maladies Pulmonaires rares de l'Adultes de Dijon, réseau OrphaLung, Filère RespiFil, Centre Hospitalier Universitaire de Bourgogne, 14, rue Paul-Gaffarel, 21000 Dijon, France; Université de Bourgogne Franche-Comté, Faculté de médecine, Dijon, France; NSERM U123-1, Dijon, France.
Abstract
OBJECTIVES: Daptomycin is a widely used antibiotic. Rhabdomyolysis related to daptomycin is one of the adverse effects of treatment, justifying the need for regular monitoring of muscle enzymes throughout treatment. Daptomycin may also lead to eosinophilic pneumonia. However, risk factors for this adverse reaction have not been identified and do not permit targeting of at-risk populations who could benefit from appropriate monitoring. PATIENTS AND METHODS: Literature was reviewed for cases of daptomycin-induced eosinophilic pneumonia (DIEP), which that were compared to cases of patients without this adverse effect. RESULTS: Fifty patients with DIEP and 54 controls were identified. Age, sex, and treatment dose are not associated with the occurrence of DIEP. A high dose of daptomycin is not associated with an early onset of DIEP. About one third of patients with eosinophilic lung disease have diabetes or renal impairment. CONCLUSIONS: Further studies may help to identify additional factors.
OBJECTIVES:Daptomycin is a widely used antibiotic. Rhabdomyolysis related to daptomycin is one of the adverse effects of treatment, justifying the need for regular monitoring of muscle enzymes throughout treatment. Daptomycin may also lead to eosinophilic pneumonia. However, risk factors for this adverse reaction have not been identified and do not permit targeting of at-risk populations who could benefit from appropriate monitoring. PATIENTS AND METHODS: Literature was reviewed for cases of daptomycin-induced eosinophilic pneumonia (DIEP), which that were compared to cases of patients without this adverse effect. RESULTS: Fifty patients with DIEP and 54 controls were identified. Age, sex, and treatment dose are not associated with the occurrence of DIEP. A high dose of daptomycin is not associated with an early onset of DIEP. About one third of patients with eosinophilic lung disease have diabetes or renal impairment. CONCLUSIONS: Further studies may help to identify additional factors.